| Dr Alexis Secor Merin, PSYD | |
|
1634 I St Nw, Suite 805, Washington, DC 20006-4003 | |
| (202) 870-0909 | |
| Not Available |
| Full Name | Dr Alexis Secor Merin |
|---|---|
| Gender | Female |
| Speciality | Psychologist |
| Location | 1634 I St Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043592603 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexis Secor Merin, PSYD 1634 I St Nw, Suite 805, Washington, DC 20006-4003 Ph: (202) 870-0909 | Dr Alexis Secor Merin, PSYD 1634 I St Nw, Suite 805, Washington, DC 20006-4003 Ph: (202) 870-0909 |
News Archive
This National Pain Week (21 – 27 July 2014), NPS MedicineWise is urging people living with pain to know how to use pain relieving medicines safely, and to have a conversation with their health professional about both the type and dose of pain relief medicine that are right for them.
A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.
Vertebral fractures are the most common of all osteoporotic fractures and can have a devastating impact on a person's quality of life.
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced data from a Phase 1 clinical trial evaluating oral ridaforolimus, its investigational mTOR inhibitor, in combination with bevacizumab (Avastin®) in heavily pretreated patients with refractory metastatic solid tumors. The data were presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organization (ECCO) and the 34th annual European Society of Medical Oncology (ESMO) taking place in Berlin, Germany.
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.
› Verified 9 days ago
Dr. Leila Bremer, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1330 New Hampshire Ave Nw, Suite 106, Washington, DC 20036 Phone: 202-887-0404 | |
Dr. Chester Wayne Bullock Jr., PSYD, MED Psychologist Medicare: Not Enrolled in Medicare Practice Location: 910 17th St Nw Ste 419, Washington, DC 20006 Phone: 202-505-2795 | |
Dr. Megan Laabs, Psychologist Medicare: Not Enrolled in Medicare Practice Location: 6900 Georgia Ave Nw, Washington, DC 20307 Phone: 202-782-8671 | |
Dana Footer, PSYD Psychologist Medicare: Medicare Enrolled Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-5000 | |
Dr. Jennifer Lee Bakalar, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2000 P St Nw Ste 408, Washington, DC 20036 Phone: 202-932-0893 | |
Dr. Karin Leah Arndt, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 4601 Connecticut Ave Nw, Suite 20, Washington, DC 20008 Phone: 716-239-0723 | |
Renee Michelle Neely-walters, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 5800 8th St Nw, Washington, DC 20011 Phone: 202-541-6608 |